Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Disability evaluation under social security (hematological disorders – childhood)
source: Social Security
year: N/A
summary/abstract:A. What hematological disorders do we evaluate under these listings?
1. We evaluate non-malignant (non-cancerous) hematological disorders, such as hemolytic anemias (107.05), disorders of thrombosis and hemostasis (107.08), and disorders of bone marrow failure (107.10). These disorders disrupt the normal development and function of white blood cells, red blood cells, platelets, and clotting-factor proteins (factors).
2. We evaluate malignant (cancerous) hematological disorders, such as lymphoma, leukemia, and multiple myeloma, under the appropriate listings in 13.00, except for two lymphomas associated with human immunodeficiency virus (HIV) infection. We evaluate primary central nervous system lymphoma associated with HIV infection under 114.11B, and primary effusion lymphoma associated with HIV infection under 114.11C.
B. What evidence do we need to document that you have a hematological disorder?
We need the following evidence to document that you have a hematological disorder:
1. A laboratory report of a definitive test that establishes a hematological disorder, signed by a physician; or
2. A laboratory report of a definitive test that establishes a hematological disorder that is not signed by a physician and a report from a physician that states you have the disorder.
read moreRelated Content
-
Preventing cognitive decline in sickle cell disease: A good night’s sleepAmong children with sickle cell disease ...
-
Mechanisms of Pain in Sickle Cell DiseaseObjectives: The hallmark of sickle cell...
-
Toronto Neuroscientist Getting Closer to Tailored Treatments for Chronic PainDaily tasks most people don't think too ...
-
New England Pediatric Sickle Cell ConsortiumThe New England Pediatric Sickle Cell Co...
-
David Williams, MDDr. Williams is the president of Dana-Fa...
-
Swee Lay Thein, MB, BS, FRCP, FRCPath, DSSwee Lay Thein is the Chief of the Sickl...
-
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.